Inolimomab Biosimilar - Research Grade

Human

IL2RA

>1mg/ml

IgG1 - kappa

CHO Cells

Anti-Mouse CD25 (PC61) In Vivo Antibody - Low Endotoxin (ICH1054), Bulk Anti-Human CD25 (7G7B6) Antibody (ICH1163), Daclizumab Biosimilar - Research Grade (ICH5021), Camidanlumab Biosimilar - Research Grade (ICH5090), Anti-Human CD25 (IB7) Antibody (ICH5189A), Vopikitug Biosimilar - Research Grade (ICH5990)

https://www.imgt.org/mAb-DB/

ICH3002

P01589

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of inolimomab, an antibody directed against the human interleukin-2 receptor alpha chain (IL2RA / CD25). It is supplied for research use only (RUO) and is not the clinical drug, nor is it intended for human or veterinary use. The recombinant human IgG1-kappa format is built around the IL2RA target to reproduce the originator's binding specificity, making it a useful reagent for probing CD25 biology in vitro and in preclinical settings. Typical research applications include use as a positive/reference binder in CD25 assays, as an isotype-matched comparator, and as a starting molecule for ADCC assay development, antibody-drug conjugate (ADC) engineering, and receptor-blockade neutralization studies. The material is offered at research grade with low endotoxin (typically <1 EU/mg, with ultra-low <0.5 EU/mg options), and in bulk milligram-to-gram quantities suitable for assay standardization, in-vitro controls, and preclinical experimental work. It provides investigators a consistent, well-characterized tool for interrogating IL-2 receptor engagement without the constraints of clinical-grade drug supply. IL2RA (CD25) is the alpha subunit of the interleukin-2 receptor. Alone it binds IL-2 with low affinity and lacks signaling capacity; assembled with the beta (CD122) and common gamma (CD132) chains it forms the high-affinity trimeric receptor that transduces IL-2 signals via JAK/STAT5, PI3K, and MAPK pathways. CD25 is highly and constitutively expressed on regulatory T cells (Tregs), where it is a canonical marker, and is upregulated on activated conventional T and B cells. IL-2 signaling through the high-affinity receptor drives T-cell proliferation, Treg maintenance, and immune homeostasis. Because CD25 marks activated lymphocytes and Tregs, it is a target of interest in transplantation, autoimmunity, and tumor immunology, and its soluble form (sCD25) is a clinical biomarker of immune activation.

IL-2 receptor subunit alpha, IL-2R subunit alpha, TAC antigen, p55, Interleukin-2 receptor subunit alpha

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks